Glucose, Activity, Diet, & Sleep Assessment Study

Metabolism Disorder, Glucose Clinical Trial

— GLADS  

Official title:

GLADS Study: Glucose, Activity, Diet, & Sleep Assessment Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05139264
• Other study ID #: AAAT6779
• Status: Completed
• Start date: May 3, 2021
• Est. completion date: February 1, 2022

Study information

• Verified date: September 2023
• Source: Columbia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

GLADS is a cross-sectional, observational study assessing free-living diet, physical activity, sleep, and glucose profile over a 2-week period in healthy adult men and women.

Description:

Monitoring free-living lifestyle behaviors can provide important information on behavioral determinants of health. New technologies have improved accessibility of ambulatory assessment of diet, biomarkers, physical activity, and sleep. The study will assess the effects of free-living diet assessed by questionnaire and sleep and physical activity measured by actigraphy on interstitial glucose measured by continuous glucose monitoring in healthy adult men and women over a 2-week period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: February 1, 2022
• Est. primary completion date: February 1, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age: 18-75 y old
• In possession of a smartphone
• English speaking
• Live in New York City metro area

Exclusion Criteria:

• Active food intake disorder

Related Conditions & MeSH terms

• Glucose Metabolism Disorders
• Metabolic Diseases
• Metabolism Disorder, Glucose

Intervention

Other:
• Observational
Observation of diet, physical activity, sleep and interstitial glucose

Locations

Country	Name	City	State
United States	Russ Berrie Medical Science Pavilion	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Columbia University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glucose	Mean, fasting, post-prandial measured by continuous glucose monitoring	2 weeks
Secondary	Sleep duration	Measured by actigraphy	2 weeks
Secondary	Sleep fragmentation	Measured by actigraphy	2 weeks
Secondary	Diet composition	Carbohydrates, fats, proteins assessed by dietary recall	2 weeks